Full-Time

Marketing Director

JCK and Luxury Events

Updated on 8/24/2026

RELX

RELX

1,001-5,000 employees

Global information analytics and decision tools

Compensation Overview

$86.6k - $144.4k/yr

Company Historically Provides H1B Sponsorship

Norwalk, CT, USA

In Person

Category
Growth & Marketing (2)
,
Required Skills
Marketing
Data Analysis

Get referred to RELX

See people who can refer or advise you

Requirements
  • Progressive marketing experience, including experience leading integrated marketing strategies and teams.
  • Proven success developing and executing marketing strategies for a brand, business unit, or major product line, preferably within business-to-business events, media, or related industries.
  • Demonstrated ability to translate business objectives into marketing strategies that drive measurable commercial results.
  • Strong commercial acumen with experience partnering closely with team leaders.
  • Experience leading, mentoring, and developing high-performing marketing professionals.
  • Experience managing stakeholders and influencing in a cross-functional, matrixed environment.
  • A strong analytical mindset with experience using customer insights and performance data to guide strategic decision-making.
  • Experience managing marketing budgets, forecasting investments, and optimizing spend to maximize return on investment.
Responsibilities
  • Lead the strategic marketing direction for assigned event brands by developing integrated marketing strategies that drive audience acquisition, customer engagement, brand equity, and revenue growth.
  • Work cross-functionally with digital, content, creative, data, operations, registration, and customer experience teams to deliver cohesive, omnichannel marketing programs.
  • Develop annual marketing plans, brand positioning, and messaging frameworks aligned with business priorities and customer needs.
  • Partner with Sales to develop marketing strategies that support exhibitor acquisition and growth segment strategy.
  • Establish and monitor key marketing performance indicators, evaluate campaign and business performance, and recommend strategic adjustments to maximize results.
  • Own and manage the marketing budget for assigned brands, ensuring resources are strategically allocated, forecasts are effectively managed, and investments maximize business impact and return on investment.
  • Partner with the Portfolio Marketing Director to support broader marketing initiatives, organizational priorities, process improvements, and the continued evolution of marketing capabilities across the department.
Desired Qualifications
  • Experience developing and executing marketing strategies within business-to-business events, media, or related industries.

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Get referred to RELX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • RELX grew H1 2026 revenue 7% and adjusted operating profit 9%.
  • RELX announced Doctrine on April 28, 2026, expanding multilingual legal AI across Europe.
  • Risk Solutions and Legal keep hiring; Mike Walsh took Risk CEO on July 1, 2026.

What critics are saying

  • Anthropic-style legal AI tools commoditize research, pressuring LexisNexis pricing during 2026.
  • Doctrine needs EU approvals and integration; failed execution wastes RELX's European AI push.
  • Exhibitions still faces event timing and Middle East disruption, hurting 2026 revenue visibility.

What makes RELX unique

  • RELX combines proprietary datasets with AI workflows across Legal, Risk, STM, and Exhibitions.
  • LexisNexis owns 200 billion legal documents, including Shepard's Citations dating to 1873.
  • Recurring subscriptions and high switching costs protect margins across mission-critical professional workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

Citybiz
Apr 28th, 2026
RELX to Acquire Legaltech Platform Doctrine in European AI Push

RELX Group has entered into an agreement to acquire French legal technology company Doctrine, a move that would expand its... Read More

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence